Esophageal Cancer Surgical Practice Guidelines
Esophageal Cancer Surgical Practice Guidelines
The Society of Surgical Oncology surgical practice guidelines focus
on the signs and symptoms of primary cancer, timely evaluation of the symptomatic
patient, appropriate preoperative extent of disease evaluation, and the
role of the surgeon in diagnosis and treatment. Separate sections on adjuvant
therapy, follow-up programs, or management of recurrent cancer have been
intentionally omitted. Where appropriate, perioperative adjuvant combined-modality
therapy is discussed under surgical management. Each guideline is presented
in minimal outline form as a delineation of therapeutic options.
Since the development of treatment protocols was not the specific aim
of the Society, the extensive development cycle necessary to produce evidence-based
practice guidelines did not apply. We used the broad clinical experience
residing in the membership of the Society, under the direction of Alfred
M. Cohen, MD, Chief, Colorectal Service, Memorial Sloan-Kettering Cancer
Center, to produce guidelines that were not likely to result in significant
Following each guideline is a brief narrative highlighting and expanding
on selected sections of the guideline document, with a few relevant references.
The current staging system for the site and approximate 5-year survival
data are also included.
The Society does not suggest that these guidelines replace good medical
judgment. That always comes first. We do believe that the family physician,
as well as the health maintenance organization director, will appreciate
the provision of these guidelines as a reference for better patient care.
Symptoms and Signs
- Early-stage disease
- Asymptomatic--picked up on routine upper gastrointestinal endoscopy
or other investigation
- Dysphagia, odynophagia, anemia, gastrointestinal bleeding
- Symptoms of locally advanced disease, eg, chest pain, upper abdominal
pain, hoarseness or tracheo-esophageal fistula with as- piration pneumonia
- Symptoms of metastatic disease (neurologic, hepatic, bone)
Evaluation of the Symptomatic Patient
- Barium swallow and upper gastrointestinal (GI) series
- CT scan
- Upper gastrointestinal endoscopy
- Prompt evaluation of patients as described above under "Symptoms
Appropriate timeliness of surgical referral
Preoperative Evaluation for Extent of Disease
- Complete history and physical examination
- Chest x-ray
- Barium swallow and upper GI series
- CT scan--chest and upper abdomen (± neck)
- Routine blood chemistries
- Endoscopic ultrasound
- Investigation for metastatic disease (bone scan, CT scan, laparoscopy)
Further investigations (where indicated by above or optional)
- Esophagoscopy plus upper GI endoscopy
- Bronchoscopy--for lesions above inferior pulmonary vein
- Laparoscopy and/or thoracoscopy when indicated--to rule out unresectable
disease or widespread metastases
Role of the Surgeon in Management
- The surgeon is expected to completely evaluate the patient and analyze
all testing that has been done or initiate such testing. This may include
a bronchoscopy, esophagoscopy, laparoscopy, and thoracoscopy.
- Cardiorespiratory evaluation
- The surgeon must be adept at performing all invasive endoscopy procedures
required for preoperative evaluation and clinical staging.
- The surgeon must be adept at performing partial and total esoph- agectomy
utilizing the intra-abdominal, transthoracic, and cervical approaches,
as necessary. Esophageal resection margins of at least 5 cm are the goal.
The surgeon must be able to utilize the colon or small intestine, as well
as the stomach, for esophageal replacement. The surgeon must be familiar
with upper abdominal and mediastinal lymph node dissection.
- Palliative maneuvers to alleviate dysphagia may include: stent insertion,
laser ablation, and esophageal bypass.
These guidelines are copyrighted by the Society of Surgical Oncology
(SSO). All rights reserved. These guidelines may not be reproduced in any
form without the express written permission of SSO. Requests for reprints
should be sent to: James R. Slawny, Executive Director, Society of Surgical
Oncology, 85 W Algonquin Road, Arlington Heights, IL 60005.
Although carcinoma of the esophagus is a relatively uncommon malignancy,
with an age-adjusted incidence of only 10 cases per 100,000 people in North
America, the incidence of esophageal adenocarcinoma is rapidly increasing
in patients with chronic reflux disease. This latter tumor is often associated
with the development of columnar-lined epithelium (Barrett's esophagus).
In some areas of the world, eg, northern China, northern Iran, and southern
Africa, squamous cell carcinoma is very common, with an age-adjusted incidence
as high as 150 cases per 100,000 males.
Whereas adenocarcinoma of the esophagus seems to be related to acid-bile
reflux disease, squamous cell carcinoma has been associated with Plummer-Vinson
syndrome in Oriental and black males, as well as Scandinavian females.
Heavy alcohol consumption and heavy tobacco intake have been implicated
as cocarcinogens for squamous cell carcinoma. Nutritional factors, such
as high nitrosamine intake and vitamin deficiencies, also have been implicated
in the production of squamous cell disease.
Screening approaches (eg, esophageal cytology, biannual endoscopy) have
been employed most frequently in high-risk geographic areas (mass screening)
and in patients identified with columnar-lined epithelium (individual screening
program). In such situations, screening has permitted earlier diagnosis